Download PDF
Semin Liver Dis 2011; 31(3): 260-271
DOI: 10.1055/s-0031-1286057
© Thieme Medical Publishers

Pathology of Hepatic Iron Overload

Yves Deugnier1 , 2 , 3 , Bruno Turlin2 , 3 , 4
  • 1CHU Rennes, Liver Unit, Rennes, France
  • 2Univ Rennes1, IFR 140, Faculty of Medicine, Rennes, France
  • 3INSERM, U 991, Department of Pathology, Rennes, France
  • 4CHU Rennes, Department of Pathology, Rennes, France
Further Information

Publication History

Publication Date:
07 September 2011 (online)

    Permissions and Reprints

ABSTRACT

The growing availability of genetic tests for most inherited iron-overload conditions and our current ability to assess hepatic iron stores, and at a lesser extent, liver fibrosis by noninvasive methods have reduced the need for liver biopsy in patients with hepatic iron excess. Histologic evaluation of the liver remains useful (1) in well-defined genetic iron overload disorders to evaluate associated hepatic damage, (2) in unclassified genetic or acquired iron excess to guide etiologic diagnosis and to establish prognosis, and (3) in research studies for a whole and reliable assessment of the liver. The identification of iron overload, the description of its cellular and lobular distribution, semiquantitative assessment of its amount, and inventory of associated lesions, especially fibrosis, are the pathologist's main objectives.

KEYWORDS

Liver pathology - iron overload - hemochromatosis

REFERENCES

  • 1 Turlin B, Deugnier Y. Evaluation and interpretation of iron in the liver.  Semin Diagn Pathol. 1998;  15 (4) 237-245
    PubMedGoogle Scholar
  • 2 Turlin B, Loreal O, Moirand R, Brissot P, Deugnier Y, Ramee M P. [Histochemical detection of hepatic iron. A comparative study of four stains].  Ann Pathol. 1992;  12 (6) 371-373
    PubMedGoogle Scholar
  • 3 Brissot P, Bourel M, Herry D et al.. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods.  Gastroenterology. 1981;  80 (3) 557-565
    PubMedGoogle Scholar
  • 4 Imbert-Bismut F, Charlotte F, Turlin B et al.. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring.  J Clin Pathol. 1999;  52 (6) 430-434
    CrossrefPubMedGoogle Scholar
  • 5 Scheuer P J, Williams R, Muir A R. Hepatic pathology in relatives of patients with haemochromatosis.  J Pathol Bacteriol. 1962;  84 53-64
    CrossrefPubMedGoogle Scholar
  • 6 Bothwell T H, Abrahams C, Bradlow B A, Charlton R W. Idiopathic and Bantu hemochromatosis. Comparative histological study.  Arch Pathol. 1965;  79 163-168
    PubMedGoogle Scholar
  • 7 Conn H O, Strauss R H, Conn M B. Estimation of hepatic hemosiderin by gross inspection of iron-stained histologic sections.  Yale J Biol Med. 1972;  45 (2) 133-138
    PubMedGoogle Scholar
  • 8 Deugnier Y M, Loréal O, Turlin B et al.. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations.  Gastroenterology. 1992;  102 (6) 2050-2059
    PubMedGoogle Scholar
  • 9 Deugnier Y M, Turlin B, Powell L W et al.. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases.  Hepatology. 1993;  17 (1) 30-34
    CrossrefPubMedGoogle Scholar
  • 10 Rowe J W, Wands J R, Mezey E et al.. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred.  Medicine (Baltimore). 1977;  56 (3) 197-211
    PubMedGoogle Scholar
  • 11 Searle J, Kerr J, Halliday J W, Powell L W. Iron storage disease. In: MacSweeen R, Anthony P, Scheuer P, eds. Pathology of the Liver. London: Churchill Livingstone; 1988: 181-201
    Google Scholar
  • 12 Turlin B, Deugnier Y. Histological assessment of liver siderosis.  J Clin Pathol. 1997;  50 (11) 971
    PubMedGoogle Scholar
  • 13 Deugnier Y, Margules S, Brissot P et al.. Comparative study between biochemical and histological methods and image analysis in liver iron overload.  J Clin Pathol. 1982;  35 (1) 45-51
    CrossrefPubMedGoogle Scholar
  • 14 Olynyk J, Hall P, Sallie R, Reed W, Shilkin K, Mackinnon M. Computerized measurement of iron in liver biopsies: a comparison with biochemical iron measurement.  Hepatology. 1990;  12 (1) 26-30
    CrossrefPubMedGoogle Scholar
  • 15 Olynyk J K, O'Neill R, Britton R S, Bacon B R. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: diagnostic implications.  Gastroenterology. 1994;  106 (3) 674-677
    PubMedGoogle Scholar
  • 16 Deugnier Y, Turlin B, le Quilleuc D et al.. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis.  Am J Surg Pathol. 1997;  21 (6) 669-675
    CrossrefPubMedGoogle Scholar
  • 17 Ludwig J, Hashimoto E, Porayko M K, Moyer T P, Baldus W P. Hemosiderosis in cirrhosis: a study of 447 native livers.  Gastroenterology. 1997;  112 (3) 882-888
    CrossrefPubMedGoogle Scholar
  • 18 Villeneuve J P, Bilodeau M, Lepage R, Côté J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens.  J Hepatol. 1996;  25 (2) 172-177
    CrossrefPubMedGoogle Scholar
  • 19 Gandon Y, Olivié D, Guyader D et al.. Non-invasive assessment of hepatic iron stores by MRI.  Lancet. 2004;  363 (9406) 357-362
    CrossrefPubMedGoogle Scholar
  • 20 Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we finally there?.  J Hepatol. 2005;  42 (1) 153-154
    PubMedGoogle Scholar
  • 21 Brunt E M, Olynyk J K, Britton R S, Janney C G, Di Bisceglie A M, Bacon B R. Histological evaluation of iron in liver biopsies: relationship to HFE mutations.  Am J Gastroenterol. 2000;  95 (7) 1788-1793
    PubMedGoogle Scholar
  • 22 Brunt E M. Pathology of hepatic iron overload.  Semin Liver Dis. 2005;  25 (4) 392-401
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Bridle K R, Crawford D H, Fletcher L M, Smith J L, Powell L W, Ramm G A. Evidence for a sub-morphological inflammatory process in the liver in haemochromatosis.  J Hepatol. 2003;  38 (4) 426-433
    CrossrefPubMedGoogle Scholar
  • 24 Fracanzani A L, Fargion S, Romano R et al.. Portal hypertension and iron depletion in patients with genetic hemochromatosis.  Hepatology. 1995;  22 (4 Pt 1) 1127-1131
    PubMedGoogle Scholar
  • 25 Adams P C. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis?.  Am J Gastroenterol. 2001;  96 (2) 567-569
    CrossrefPubMedGoogle Scholar
  • 26 Powell L W, Dixon J L, Ramm G A et al.. Screening for hemochromatosis in asymptomatic subjects with or without a family history.  Arch Intern Med. 2006;  166 (3) 294-301
    CrossrefPubMedGoogle Scholar
  • 27 Falize L, Guillygomarc'h A, Perrin M et al.. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.  Hepatology. 2006;  44 (2) 472-477
    CrossrefPubMedGoogle Scholar
  • 28 Guyader D, Jacquelinet C, Moirand R et al.. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.  Gastroenterology. 1998;  115 (4) 929-936
    CrossrefPubMedGoogle Scholar
  • 29 George D K, Ramm G A, Walker N I, Powell L W, Crawford D H. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis.  J Hepatol. 1999;  31 (1) 47-52
    PubMedGoogle Scholar
  • 30 Crawford D H, Murphy T L, Ramm L E et al.. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis.  Hepatology. 2009;  49 (2) 418-425
    CrossrefPubMedGoogle Scholar
  • 31 Morrison E D, Brandhagen D J, Phatak P D et al.. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis.  Ann Intern Med. 2003;  138 (8) 627-633
    PubMedGoogle Scholar
  • 32 Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis.  Hepatology. 2002;  36 (3) 673-678
    CrossrefPubMedGoogle Scholar
  • 33 Adhoute X, Foucher J, Laharie D et al.. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study.  Gastroenterol Clin Biol. 2008;  32 (2) 180-187
    CrossrefPubMedGoogle Scholar
  • 34 Kowdley K V. Iron, hemochromatosis, and hepatocellular carcinoma.  Gastroenterology. 2004;  127 (5, Suppl 1) S79-S86
    CrossrefPubMedGoogle Scholar
  • 35 Bradbear R A, Bain C, Siskind V et al.. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases.  J Natl Cancer Inst. 1985;  75 (1) 81-84
    PubMedGoogle Scholar
  • 36 Fracanzani A L, Conte D, Fraquelli M et al.. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease.  Hepatology. 2001;  33 (3) 647-651
    CrossrefPubMedGoogle Scholar
  • 37 Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch H J, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.  N Engl J Med. 1985;  313 (20) 1256-1262
    CrossrefPubMedGoogle Scholar
  • 38 Deugnier Y M, Guyader D, Crantock L et al.. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases.  Gastroenterology. 1993;  104 (1) 228-234
    PubMedGoogle Scholar
  • 39 Morcos M, Dubois S, Bralet M P, Belghiti J, Degott C, Terris B. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum.  Am J Clin Pathol. 2001;  116 (5) 738-743
    CrossrefPubMedGoogle Scholar
  • 40 Deugnier Y M, Charalambous P, Le Quilleuc D et al.. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients.  Hepatology. 1993;  18 (6) 1363-1369
    CrossrefPubMedGoogle Scholar
  • 41 Blanc J F, Bernard P H, Carles J, Le Bail B, Balabaud C, Bioulac-Sage P. Cholangiocarcinoma arising in Von Meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis.  Eur J Gastroenterol Hepatol. 2000;  12 (2) 233-237
    CrossrefPubMedGoogle Scholar
  • 42 Pietrangelo A. The ferroportin disease.  Blood Cells Mol Dis. 2004;  32 (1) 131-138
    CrossrefPubMedGoogle Scholar
  • 43 Island M L, Jouanolle A M, Mosser A et al.. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis.  Haematologica. 2009;  94 (5) 720-724
    CrossrefPubMedGoogle Scholar
  • 44 Milet J, Dehais V, Bourgain C et al.. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance.  Am J Hum Genet. 2007;  81 (4) 799-807
    CrossrefPubMedGoogle Scholar
  • 45 Nahon P, Sutton A, Pessayre D et al.. Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis?.  Antioxid Redox Signal. 2011;  15 (1) 31-38
    CrossrefPubMedGoogle Scholar
  • 46 Le Lan C, Mosser A, Ropert M et al.. Sex and acquired cofactors determine phenotypes of ferroportin disease.  Gastroenterology. 2011;  140 (4) 1199-1207 e1-e2
    CrossrefPubMedGoogle Scholar
  • 47 Rosmorduc O, Wendum D, Arrivé L et al.. Phenotypic expression of ferroportin disease in a family with the N144H mutation.  Gastroenterol Clin Biol. 2008;  32 (3) 321-327
    CrossrefPubMedGoogle Scholar
  • 48 Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism.  Biometals. 2003;  16 (1) 205-213
    CrossrefPubMedGoogle Scholar
  • 49 Kono S, Suzuki H, Takahashi K et al.. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia.  Gastroenterology. 2006;  131 (1) 240-245
    CrossrefPubMedGoogle Scholar
  • 50 Beutler E, Gelbart T, Lee P, Trevino R, Fernandez M A, Fairbanks V F. Molecular characterization of a case of atransferrinemia.  Blood. 2000;  96 (13) 4071-4074
    PubMedGoogle Scholar
  • 51 Gordeuk V R. African iron overload.  Semin Hematol. 2002;  39 (4) 263-269
    CrossrefPubMedGoogle Scholar
  • 52 Gordeuk V, Mukiibi J, Hasstedt S J et al.. Iron overload in Africa. Interaction between a gene and dietary iron content.  N Engl J Med. 1992;  326 (2) 95-100
    CrossrefPubMedGoogle Scholar
  • 53 Deugnier Y, Loréal O, Carré F et al.. Increased body iron stores in elite road cyclists.  Med Sci Sports Exerc. 2002;  34 (5) 876-880
    CrossrefPubMedGoogle Scholar
  • 54 Deugnier Y, Brissot P, Loréal O. Iron and the liver: update 2008.  J Hepatol. 2008;  48 (Suppl 1) S113-S123
    PubMedGoogle Scholar
  • 55 Nahon P, Ganne-Carrié N, Trinchet J C, Beaugrand M. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis.  Gastroenterol Clin Biol. 2010;  34 (1) 1-7
    PubMedGoogle Scholar
  • 56 Jakobovits A W, Morgan M Y, Sherlock S. Hepatic siderosis in alcoholics.  Dig Dis Sci. 1979;  24 (4) 305-310
    CrossrefPubMedGoogle Scholar
  • 57 Harrison-Findik D D. Role of alcohol in the regulation of iron metabolism.  World J Gastroenterol. 2007;  13 (37) 4925-4930
    PubMedGoogle Scholar
  • 58 Brunt E M. Pathology of nonalcoholic steatohepatitis.  Hepatol Res. 2005;  33 (2) 68-71
    CrossrefPubMedGoogle Scholar
  • 59 Valenti L, Fracanzani A L, Bugianesi E et al.. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.  Gastroenterology. 2010;  138 (3) 905-912
    CrossrefPubMedGoogle Scholar
  • 60 Nelson J E, Wilson L, Brunt E M Nonalcoholic Steatohepatitis Clinical Research Network et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease.  Hepatology. 2011;  53 (2) 448-457
    CrossrefPubMedGoogle Scholar
  • 61 Mendler M H, Turlin B, Moirand R et al.. Insulin resistance-associated hepatic iron overload.  Gastroenterology. 1999;  117 (5) 1155-1163
    CrossrefPubMedGoogle Scholar
  • 62 Moirand R, Mortaji A M, Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation.  Lancet. 1997;  349 (9045) 95-97
    CrossrefPubMedGoogle Scholar
  • 63 Turlin B, Mendler M H, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients.  Am J Clin Pathol. 2001;  116 (2) 263-270
    CrossrefPubMedGoogle Scholar
  • 64 Bekri S, Gual P, Anty R et al.. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.  Gastroenterology. 2006;  131 (3) 788-796
    CrossrefPubMedGoogle Scholar
  • 65 Lainé F, Deugnier Y. Increased expression of hepcidin in obese patients: impact on phenotypic expression of hemochromatosis and pathophysiology of dysmetabolic iron overload syndrome.  Gastroenterology. 2006;  131 (6) 2028
    CrossrefPubMedGoogle Scholar
  • 66 Lainé F, Jouannolle A M, Morcet J et al.. Phenotypic expression in detected C282Y homozygous women depends on body mass index.  J Hepatol. 2005;  43 (6) 1055-1059
    CrossrefPubMedGoogle Scholar
  • 67 Bonkovsky H L, Lambrecht R W, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease.  Alcohol. 2003;  30 (2) 137-144
    CrossrefPubMedGoogle Scholar
  • 68 Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C.  Hum Pathol. 1995;  26 (10) 1080-1085
    CrossrefPubMedGoogle Scholar
  • 69 Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.  Gut. 1997;  41 (1) 115-120
    CrossrefPubMedGoogle Scholar
  • 70 Fontana R J, Israel J, LeClair P et al.. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.  Hepatology. 2000;  31 (3) 730-736
    CrossrefPubMedGoogle Scholar
  • 71 Fujita N, Sugimoto R, Takeo M et al.. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.  Mol Med. 2007;  13 (1-2) 97-104
    PubMedGoogle Scholar
  • 72 Hayashi H, Yano M, Fujita Y, Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease.  Med Mol Morphol. 2006;  39 (3) 121-126
    CrossrefPubMedGoogle Scholar
  • 73 Alla V, Bonkovsky H L. Iron in nonhemochromatotic liver disorders.  Semin Liver Dis. 2005;  25 (4) 461-472
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Cotler S J, Bronner M P, Press R D et al.. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index.  J Hepatol. 1998;  29 (2) 257-262
    CrossrefPubMedGoogle Scholar
  • 75 Brissot P, Wright T L, Ma W L, Weisiger R A. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.  J Clin Invest. 1985;  76 (4) 1463-1470
    CrossrefPubMedGoogle Scholar
  • 76 Détivaud L, Nemeth E, Boudjema K et al.. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function.  Blood. 2005;  106 (2) 746-748
    CrossrefPubMedGoogle Scholar
  • 77 Kijima H, Sawada T, Tomosugi N, Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma.  BMC Cancer. 2008;  8 167
    CrossrefPubMedGoogle Scholar
  • 78 Turlin B, Juguet F, Moirand R et al.. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver.  Hepatology. 1995;  22 (2) 446-450
    PubMedGoogle Scholar
  • 79 Ko C, Siddaiah N, Berger J et al.. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry.  Liver Int. 2007;  27 (10) 1394-1401
    CrossrefPubMedGoogle Scholar
  • 80 Nahon P, Sutton A, Rufat P et al.. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis.  Gastroenterology. 2008;  134 (1) 102-110
    CrossrefPubMedGoogle Scholar
  • 81 Deugnier Y, Turlin B. Iron and hepatocellular carcinoma.  J Gastroenterol Hepatol. 2001;  16 (5) 491-494
    CrossrefPubMedGoogle Scholar
  • 82 Bottomley S S. Secondary iron overload disorders.  Semin Hematol. 1998;  35 (1) 77-86
    PubMedGoogle Scholar
  • 83 Cappellini M D, Cohen A, Piga A et al.. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.  Blood. 2006;  107 (9) 3455-3462
    CrossrefPubMedGoogle Scholar
  • 84 Deugnier Y, Turlin B, Ropert M et al.. Semi-quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade®, ICL670) or deferoxamine in patients with transfusion-dependent anemia.  Blood. 2005;  106 (11) abstract #912
    PubMedGoogle Scholar
  • 85 Deugnier Y, Turlin B, Ropert M et al.. Improvement in liver pathology in patients with β thalassemia treated with deferasirox for at least 3 years.  Gastroenterology. 2011;  In press
    PubMedGoogle Scholar
  • 86 Mirault T, Lucidarme D, Turlin B et al.. Non-invasive assessment of liver fibrosis by transient elastography in post transfusional iron overload.  Eur J Haematol. 2008;  80 (4) 337-340
    CrossrefPubMedGoogle Scholar
  • 87 Walsh A, Dixon J L, Ramm G A et al.. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis.  Clin Gastroenterol Hepatol. 2006;  4 (11) 1403-1410
    CrossrefPubMedGoogle Scholar

Yves DeugnierM.D. 

Service des maladies du foie, CHU, Hôpital Pontchaillou

35033 Rennes, France

Email: yves.deugnier@univ-rennes1.fr

      >